Novo Outbid As Sanofi Agrees €3.9bn Ablynx Acquisition
Executive Summary
Sanofi is to acquire Belgian nanobody developer Ablynx in an all-cash deal worth €3.9bn, 50% higher than the spurned bid by Novo Nordisk.
| Table |
|---|
Advertisement
Related Content
Keeping Track: CDER Approves Its First Two Novel Agents Of 2019
Keeping Track: J&J Esketamine, Sanofi Caplacizumab Lead Off September Submissions; US FDA Says No To Nucala
Exosome Pioneer Evox's Series B Gives It Needed Financial Runway, CEO Says
Deal Watch: Amazon Moves Into Rx Services With Acquisition Of PillPack
Cablivi CHMP Backing Helps Validate Sanofi's €3.9bn Ablynx Purchase
Biopharma Quarterly Dealmaking Statistics, Q1 2018
Deal Watch: As J.P. Morgan Waits For New Deals, Sanofi Takes Care Of Old Business
Novo's €2.6bn Ablynx Bid Opens The Door For Better Offers
Novo Nordisk Offers €2.6bn For Ablynx
Ablynx Adds Sanofi To Its List Of Big Pharma Partners
Topics
- Subjects
- M & A
- Commercial
- Industries
- BioPharmaceutical
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC100281
Ask The Analyst
Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
SC100281
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.